Product
TAD
Aliases
TAD® 600 mg/4 mL powder and solvent for solution for injection
1 clinical trial
2 indications
Indication
PneumoniaIndication
Myocardial InjuryClinical trial
Multicenter, Randomized, Double-blind, Phase III Study of Intravenous TAD® 600 mg/4 mL Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients With Pneumonia.Status: Not yet recruiting, Estimated PCD: 2024-09-30